Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001493152-24-034869
Filing Date
2024-09-03
Accepted
2024-09-03 17:29:25
Documents
21

Document Format Files

Seq Description Document Type Size
1 forms-3.htm   iXBRL S-3 407234
2 ex5-1.htm EX-5.1 55690
3 ex23-1.htm EX-23.1 3114
4 ex23-2.htm EX-23.2 4061
5 CALCULATION OF FILING FEE TABLES ex107.htm EX-FILING FEES 110243
6 forms-3_001.jpg GRAPHIC 4605
7 ex5-1_001.jpg GRAPHIC 17875
8 ex5-1_002.jpg GRAPHIC 54892
  Complete submission text file 0001493152-24-034869.txt   967324

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE zvsa-20240903.xsd EX-101.SCH 3257
10 XBRL DEFINITION FILE zvsa-20240903_def.xml EX-101.DEF 26194
11 XBRL LABEL FILE zvsa-20240903_lab.xml EX-101.LAB 35964
12 XBRL PRESENTATION FILE zvsa-20240903_pre.xml EX-101.PRE 24852
23 EXTRACTED XBRL INSTANCE DOCUMENT forms-3_htm.xml XML 4704
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-281914 | Film No.: 241275174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)